Eidos Therapeutics (Eidos Therapeutics) EBIT per Share : $-2.59 (TTM As of Sep. 2020)

View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics EBIT per Share?

Eidos Therapeutics's EBIT per Share for the three months ended in Sep. 2020 was $-0.77. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2020 was $-2.59.

During the past 3 years, the average EBIT per Share Growth Rate was -104.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Eidos Therapeutics's EBIT per Share or its related term are showing as below:

EIDX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -104.6 Med: -104.6 Max: -104.6
Current: -104.6

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Eidos Therapeutics was -104.60% per year. The lowest was -104.60% per year. And the median was -104.60% per year.

EIDX's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.7 vs EIDX: -104.60

Eidos Therapeutics's EBIT for the three months ended in Sep. 2020 was $-29.41 Mil.

Eidos Therapeutics EBIT per Share Historical Data

The historical data trend for Eidos Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics EBIT per Share Chart

Eidos Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

EBIT per Share

-0.12

-0.61

-1.86

-1.02

Eidos Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
EBIT per Share	Get a 7-Day Free Trial											0.18	-0.50	-0.59	-0.74	-0.77

Eidos Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Eidos Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2019 is calculated as

	EBIT per Share		(A: Dec. 2019 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-37.508	/	36.625
=	-1.02

Eidos Therapeutics's EBIT per Share for the quarter that ended in Sep. 2020 is calculated as

	EBIT per Share		(Q: Sep. 2020 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-29.41	/	38.389
=	-0.77

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.59

Eidos Therapeutics (NAS:EIDX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Eidos Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Eidos Therapeutics (Eidos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (NAS:EIDX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104

Website

https://www.eidostx.com

Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Executives

Uma Sinha	director, officer: Chief Scientific Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Franco Valle	officer: Senior Vice President, Finance	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Cameron Turtle	officer: Chief Business Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Jonathan C Fox	officer: See Remarks	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Sawochka Hooper	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Douglas Rohlen	director	3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447
Eric Aguiar	director	888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali J. Satvat	director, 10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Christine Siu	officer: CFO and Secretary	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Bridgebio Pharma, Inc.	10 percent owner	421 KIPLING STREET PALO ALTO CA 94301
Neil Kumar	director, 10 percent owner, officer: Chief Executive Officer	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Hoyoung Huh	director	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116